p53 and Δnp63α differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis

Oncogene

Volumn 26, Issue 42, 2007, Pages 6125-6132

  Schavolt, K L ^a   Pietenpol, J A ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

14 3 36; Fas APO1; Noxa; p21; p48; p53R2

Indexed keywords

PROTEIN; PROTEIN DELTANP63ALPHA; PROTEIN P53; RNA POLYMERASE II; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BAY REGION BINDING SITE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; FUNCTIONAL PROTEOMICS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KERATINOCYTE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

APOPTOSIS; CELL CYCLE; CELLS, CULTURED; DNA REPAIR; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; MULTIGENE FAMILY; PROTEIN BINDING; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 34548671621     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210441     Document Type: Article

References (28)

1. Appella E, Anderson CW. (2001). Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268: 2764-2772.
2. Bakkers J, Hild M, Kramer C, Furutani-Seiki M, Hammerschmidt M. (2002). Zebrafish DeltaNp63 is a direct target of Bmp signaling and encodes a transcriptional repressor blocking neural specification in the ventral ectoderm. Dev Cell 2: 617-627.
3. Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, Pietenpol JA. (2005). IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res 65: 2314-2320.
4. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. (2006). Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 66: 7589-7597.
5. Beretta C, Chiarelli A, Testoni B, Mantovani R, Guerrini L. (2005). Regulation of the cyclin-dependent kinase inhibitor p57Kip2 expression by p63. Cell Cycle 4: 1625-1631.
6. Bode AM, Dong Z. (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805.
7. Dohn M, Zhang S, Chen X. (2001). p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20: 3193-3205.
8. Dumaz N, Meek DW. (1999). Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 18: 7002-7010.
9. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
10. Espinosa JM, Verdun RE, Emerson BM. (2003). p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 12: 1015-1027.
11. Harms K, Nozell S, Chen X. (2004). The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61: 822-842.
12. Hermeking H, Lengauer C, Polyak K, He T-C, Zhang L, Thiagalingam S et al. (1997). 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11.
13. Ihrie RA, Marques MR, Nguyen BT, Horner JS, Papazoglu C, Bronson RT et al. (2005). Perp is a p63-regulated gene essential for epithelial integrity. Cell 120: 843-856.
14. Jacobs WB, Govoni G, Ho D, Atwal JK, Barnabe-Heider F, Keyes WM et al. (2005). p63 is an essential proapoptotic protein during neural development. Neuron 48: 743-756.
15. Kaeser MD, Iggo RD. (2002). Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 99: 95-100.
16. Kaeser MD, Iggo RD. (2004). Promoter-specific p53-dependent histone acetylation following DNA damage. Oncogene 23: 4007-4013.
17. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. (1998). Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273: 33048-33053.
18. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M et al. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045.
19. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058.
20. Qian H, Wang T, Naumovski L, Lopez CD, Brachmann RK. (2002). Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 21: 7901-7911.
21. Sasaki Y, Naishiro Y, Oshima Y, Imai K, Nakamura Y, Tokino T. (2005). Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. Oncogene 24: 5131-5136.
22. Szak ST, Mays D, Pietenpol JA. (2001). Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 21: 3375-3386.
23. Tan T, Chu G. (2002). p53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol 22: 3247-3254.
24. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K et al. (2000). A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42-49.
25. Weinberg RL, Veprintsev DB, Bycroft M, Fersht AR. (2005). Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol 348: 589-596.
26. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. (2003). The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 23: 2264-2276.
27. Westfall MD, Pietenpol JA. (2004). p63: Molecular complexity in development and cancer. Carcinogenesis 25: 857-864.
28. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. (1995). A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23: 2584-2592.